Dr. Juan Daniel Cuevas, MD

Dr. Cuevas practices at St. Louis Cancer Care in Saint Louis, Missouri.

Dr. Cuevas' NPI, 1295727493, was assigned on August 16, 2005. Dr. Cuevas holds Missouri license 103666.

Dr. Cuevas' primary practice is St. Louis Cancer Care, at 10004 Kennerly Rd, Saint Louis, MO 63128 in Saint Louis County. The practice phone is (314) 842-7301.

Dr. Cuevas' primary practice is St. Louis Cancer Care in Saint Louis, Missouri. Dr. Cuevas is also affiliated with Mercy Hospital St. Louis. The medical group on file is St. Louis Cancer Care. Dmand AI also links Dr. Cuevas to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cuevas practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Cuevas' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cuevas is licensed in Missouri.

CMS data shows 16,186 Medicare services from Dr. Cuevas across 22 procedure codes in 2024, for 235 Medicare patients. Medicare paid $334,459 for them.

CMS counts 235 Medicare patients who saw Dr. Cuevas in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cuevas' median patient age at 73, with 63% women.

In 2024, Dr. Cuevas wrote 1,491 Medicare Part D claims for 276 patients. 78% of them were for generic drugs. CMS names the drug for 1,345 of them, across 35 drugs with 11 or more claims each, at $4,085,459 in total drug cost. In 2023, CMS named 1,292 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Cuevas for performance year 2024, reported as part of a group. Dr. Cuevas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Cuevas in 2023. Dr. Cuevas' most frequent co-authors are Joanne Lorraine Blum, MD, Gabrielle Betty Rocque and Bijoy Pankaj Telivala, MD.

Dmand AI links Dr. Cuevas to 7 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Neoplasm Metastasis. G1 Therapeutics, Inc. sponsors the most, 3. Open Payments lists research payments to Dr. Cuevas that name 1 trial.

CMS Open Payments shows 428 general payments to Dr. Cuevas from 51 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 52% of the total. Bristol-Myers Squibb Company paid the most, $6,385. It also lists 9 research payments totaling $7,419 from 2019 to 2023, naming 1 clinical trial.